Prestige Consumer Healthcare reported a top and bottom-line beat for the second quarter of fiscal 2027, driven primarily by strong contributions from the Breathe Right and LaCorium acquisitions. However, the company lowered its full-year 2027 outlook to reflect production variability and limited product availability for the Clear Eyes brand at its Pillar5 facility.
Key Highlights
- Reported revenue of $336.3 million increased 22.7% year-over-year, exceeding the consensus estimate of $329.15 million.
- Adjusted diluted EPS of $1.13 grew 5.6% versus the prior year and beat analyst expectations of $1.06.
- Organic revenue declined 1.6% during the quarter, as acquisition contributions of $65.1 million were partially offset by order timing headwinds and a decline in Clear Eyes sales.
- Fiscal 2027 revenue guidance was revised downward to a range of $1.28 billion to $1.29 billion, compared to the previous outlook of $1.29 billion to $1.315 billion.